NCT00690573 - Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

September 30, 2011

Conditions

Juvenile Rheumatoid Arthritis

Interventions

BIOLOGICAL

Adalimumab

Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).

Trial Locations (12)

Unknown

Site Reference ID/Investigator# 47248, Aichi

Site Reference ID/Investigator# 47253, Fukuoka

Site Reference ID/Investigator# 47251, Hyōgo

Site Reference ID/Investigator# 47254, Kagoshima

Site Reference ID/Investigator# 47250, Kobe

Site Reference ID/Investigator# 47255, Okinawa

Site Reference ID/Investigator# 7153, Sendai

Site Reference ID/Investigator# 47249, Takatsuki

Site Reference ID/Investigator# 47243, Tokyo

Site Reference ID/Investigator# 47244, Tokyo

Site Reference ID/Investigator# 47245, Tokyo

Site Reference ID/Investigator# 47246, Yokohama